Prime Medicine (PRME) Stock Price, News & Analysis

Company Overview

Prime Medicine, Inc. is a biotechnology company developing genetic medicines based on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company’s platform is intended to address disease-causing genetic mutations without necessarily creating double-strand breaks in DNA.

Prime Medicine is applying its technology to develop treatments for a range of genetic diseases, with a focus on areas such as hematology, immunology and liver disorders. Its pipeline has included PM359, an investigational ex vivo gene-editing therapy being developed for chronic granulomatous disease, a rare inherited immune disorder. The company continues to evaluate additional programs based on its prime-editing platform.

Founded in 2019 and headquartered in Cambridge, Massachusetts, Prime Medicine was co-founded by geneticist David R. Liu and researcher Andrew Anzalone, who helped develop prime-editing technology. The company conducts research and clinical development intended for patients in multiple international markets, although its therapies remain investigational and are not broadly approved for commercial use.

Key Stats

• Today's Range: $3.77 to $4.23
• 50-Day Range: $2.88 to $5.36
• 52-Week Range: $2.67 to $5.91
• Volume: 4.45 million shs
• Average Volume: 5.30 million shs
• Market Capitalization: $707.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.41
• Consensus Rating: Moderate Buy

Prime Medicine Stock Analysis - MarketRank™

Prime Medicine scored higher than 75% of companies evaluated by MarketBeat, and ranked 290th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Prime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Prime Medicine has a consensus price target of $7.41, representing about 89.9% upside from its current price of $3.90.

Amount of Analyst Coverage

Prime Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Prime Medicine are expected to grow in the coming year, from ($0.97) to ($0.87) per share.

Price to Book Value per Share Ratio

Prime Medicine has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

19.14% of the float of Prime Medicine has been sold short.

Short Interest Ratio / Days to Cover

Prime Medicine has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Prime Medicine has recently decreased by 11.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prime Medicine does not currently pay a dividend.

Dividend Growth

Prime Medicine does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.00

News Sentiment

Prime Medicine has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Prime Medicine this week, compared to 3 articles on an average week.

Search Interest

Only 10 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prime Medicine insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.04% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PRME
• Previous Symbol: NASDAQ:PRME
• CIK: 1894562
• Web: primemedicine.com
• Phone: (617) 465-0013
• Fax: N/A
• Employees: 146
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Prime Medicine: $7.41
• High Price Target: $11.00
• Low Price Target: $4.25
• Potential Upside/Downside: +89.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$201.14 million
• Net Margins: -4,613.11%
• Pretax Margin: -4,613.11%
• Return on Equity: -188.27%
• Return on Assets: -59.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.05
• Quick Ratio: 3.05

Sales & Book Value

• Annual Sales: $4.63 million
• Price / Sales: 152.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 5.82

Miscellaneous

• Outstanding Shares: 181,380,000
• Free Float: 152,284,000
• Market Cap: $707.38 million
• Optionable: Optionable
• Beta: 2.14